oxcarbazepine 300 MG Oral Tablet [Trileptal]

Verify with CMS →

oxcarbazepine

RxCUI: 261360

Important: Drug coverage and costs vary by plan and location. Verify coverage directly with your Medicare plan before filling a prescription. This is informational data only and should not replace advice from your healthcare provider or pharmacist.
1.5%
Plan Coverage
76
Plans Covering
T2.5
Avg Tier
0%
Prior Auth Required

What the CMS Formulary Data Shows for oxcarbazepine 300 MG Oral Tablet [Trileptal]

Per the CMS 2026 Part D formulary file, oxcarbazepine 300 MG Oral Tablet [Trileptal] (RxNorm concept RXCUI 261360, generic name oxcarbazepine) appears on 2 distinct formulary files spanning 76 Medicare Part D plan offerings - 1.5% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 2.5.

Real-world access to oxcarbazepine 300 MG Oral Tablet [Trileptal] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 195,822 Part D beneficiaries filled oxcarbazepine 300 MG Oral Tablet [Trileptal] in 2023, with total plan-and-beneficiary spending of $70,874,035 and an average per-beneficiary annual cost of $361.93. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry oxcarbazepine 300 MG Oral Tablet [Trileptal] today.

Coverage Details

Formularies covering
2
Plans covering
76
Coverage rate
1.5%
Tier range
Tier 1 – Tier 4
Average tier
Tier 3, Preferred Brand

Restrictions

Prior authorization required
0% of formularies
Step therapy required
0% of formularies
Quantity limits
0% of formularies

2023 Medicare Spending

Beneficiaries
195,822
Total spending
$70,874,035
Avg per beneficiary
$361.93

Tier Distribution Across Plans

2 plans
Tier 1, Preferred Generic
74 plans
Tier 4, Non-Preferred

Medicare Advantage Plans (MA-PD) Covering oxcarbazepine 300 MG Oral Tablet [Trileptal]

76 Medicare Advantage plans with Part D drug coverage include this drug.

Plan Insurer Tier PA Premium States
Hamaspik Medicare Choice (HMO D-SNP) HAMASPIK, INC. T1 No $0 NY
Hamaspik Medicare Select (HMO D-SNP) HAMASPIK, INC. T1 No $34.50 NY
SCAN Connections (HMO D-SNP) SCAN HEALTH PLAN T4 No $0 CA
SCAN Connections at Home (HMO D-SNP) SCAN HEALTH PLAN T4 No $0 CA
SCAN Classic (HMO) SCAN HEALTH PLAN NEVADA, INC. T4 No $0 NV
SCAN Balance (HMO C-SNP) SCAN HEALTH PLAN NEVADA, INC. T4 No $0 NV
SCAN Strive (HMO C-SNP) SCAN HEALTH PLAN NEVADA, INC. T4 No $0 NV
SCAN MyChoice (HMO) SCAN HEALTH PLAN NEVADA, INC. T4 No $0 NV
SCAN Classic (HMO) SCAN DESERT HEALTH PLAN, INC. T4 No $0 AZ
SCAN Balance (HMO C-SNP) SCAN DESERT HEALTH PLAN, INC. T4 No $0 AZ
SCAN Embrace (HMO-POS I-SNP) SCAN DESERT HEALTH PLAN, INC. T4 No $0 AZ
SCAN Strive (HMO C-SNP) SCAN DESERT HEALTH PLAN, INC. T4 No $0 AZ
SCAN MyChoice (HMO) SCAN DESERT HEALTH PLAN, INC. T4 No $0 AZ
SCAN Classic WA (HMO) SCAN HEALTH PLAN (WA) T4 No $0 WA
SCAN MyChoice WA (HMO) SCAN HEALTH PLAN (WA) T4 No $0 WA
SCAN Classic (HMO) SCAN HEALTH PLAN (NM) T4 No $0 NM
SCAN Balance (HMO C-SNP) SCAN HEALTH PLAN (NM) T4 No $0 NM
SCAN Strive (HMO C-SNP) SCAN HEALTH PLAN (NM) T4 No $0 NM
SCAN MyChoice (HMO) SCAN HEALTH PLAN (NM) T4 No $0 NM
SCAN Classic (HMO) SCAN HEALTH PLAN T4 No $0 CA
SCAN Classic (HMO) SCAN HEALTH PLAN T4 No $0 CA
SCAN Classic (HMO) SCAN HEALTH PLAN T4 No $0 CA
SCAN Classic (HMO) SCAN HEALTH PLAN T4 No $0 CA
SCAN Classic (HMO) SCAN HEALTH PLAN T4 No $0 CA
SCAN Classic (HMO) SCAN HEALTH PLAN T4 No $0 CA
SCAN Classic (HMO) SCAN HEALTH PLAN T4 No $0 CA
SCAN Balance (HMO C-SNP) SCAN HEALTH PLAN T4 No $0 CA
SCAN Prime (HMO) SCAN HEALTH PLAN T4 No $0 CA
SCAN Classic (HMO) SCAN HEALTH PLAN T4 No $0 CA
SCAN Balance (HMO C-SNP) SCAN HEALTH PLAN T4 No $0 CA
SCAN Classic (HMO) SCAN HEALTH PLAN T4 No $0 CA
SCAN Balance (HMO C-SNP) SCAN HEALTH PLAN T4 No $0 CA
SCAN Alta (HMO) SCAN HEALTH PLAN T4 No $0 CA
SCAN Venture (HMO) SCAN HEALTH PLAN T4 No $0 CA
SCAN Venture (HMO) SCAN HEALTH PLAN T4 No $0 CA
SCAN Embrace (HMO I-SNP) SCAN HEALTH PLAN T4 No $0 CA
SCAN Embrace (HMO I-SNP) SCAN HEALTH PLAN T4 No $0 CA
SCAN Embrace (HMO-POS I-SNP) SCAN HEALTH PLAN T4 No $0 CA
SCAN Affirm partnered with Included LGBTQ+ Health (HMO) SCAN HEALTH PLAN T4 No $0 CA
SCAN Affirm partnered with Included LGBTQ+ Health (HMO) SCAN HEALTH PLAN T4 No $0 CA
SCAN Strive (HMO C-SNP) SCAN HEALTH PLAN T4 No $0 CA
SCAN Strive (HMO C-SNP) SCAN HEALTH PLAN T4 No $0 CA
SCAN Inspired by women for women (HMO) SCAN HEALTH PLAN T4 No $0 CA
SCAN Classic (HMO) SCAN HEALTH PLAN T4 No $0 CA
SCAN Balance (HMO C-SNP) SCAN HEALTH PLAN T4 No $0 CA
SCAN Balance (HMO C-SNP) SCAN HEALTH PLAN T4 No $0 CA
SCAN Balance (HMO C-SNP) SCAN HEALTH PLAN T4 No $0 CA
SCAN Balance (HMO C-SNP) SCAN HEALTH PLAN T4 No $0 CA
SCAN Affirm partnered with Included LGBTQ+ Health (HMO) SCAN HEALTH PLAN T4 No $0 CA
SCAN MyChoice (HMO) SCAN HEALTH PLAN T4 No $0 CA

Frequently Asked Questions

Is oxcarbazepine 300 MG Oral Tablet [Trileptal] covered by Medicare Part D?

Yes, oxcarbazepine 300 MG Oral Tablet [Trileptal] is covered by 76 Medicare Part D plans (1.5% of all Part D formularies).

What tier is oxcarbazepine 300 MG Oral Tablet [Trileptal] on Medicare Part D plans?

oxcarbazepine 300 MG Oral Tablet [Trileptal] averages Tier 2.5 across Part D plans, ranging from Tier 1 to Tier 4.

Does oxcarbazepine 300 MG Oral Tablet [Trileptal] require prior authorization?

0% of Part D formularies require prior authorization for oxcarbazepine 300 MG Oral Tablet [Trileptal]. Step therapy: 0%. Quantity limits: 0%.

How much does Medicare spend on oxcarbazepine 300 MG Oral Tablet [Trileptal]?

In 2023, total Medicare Part D spending on oxcarbazepine 300 MG Oral Tablet [Trileptal] was $70,874,035, covering 195,822 beneficiaries. The average spend per beneficiary was $361.93.

Data sourced from the Centers for Medicare & Medicaid Services (CMS). See our methodology for details. Retrieved and formatted by PlainMedicare Editorial